证券代码：300723 证券简称：一品红 公告编号：2025-085 一品红药业集团股份有限公司 关于芩香清解口服液获批国家中药保护品种的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 芩香清解口服液用于疏风解热，清泻里热，解毒利咽，在临床上主要用于小 儿上呼吸道感染属表里俱热证，并先后获得《中成药治疗儿童流感临床应用指南 （2024 年）》《天津市冬春季流感中医药防治方案（试行）》和《湖南省冬春 季流感中医药防治方案（2025 年版）》等指南及方案推荐。 本次芩香清解口服液获批为国家中药二级保护品种，有利于强化对公司产品 的知识产权保护，有利于提升该产品在儿童药领域的市场竞争力，对公司的生产 经营产生积极的影响。 上述事项不会对公司当期经营业绩产生重大影响，药品的销售情况可能受到 国家政策、市场环境变化等因素影响，具有较大不确定性。敬请广大投资者谨慎 决策，注意投资风险。 特此公告。 一品红药业集团股份有限公司董事会 2025 年 12 月 14 日 2025 年 12 月 12 日，国家药品监督管理局网站发布了《中药保护品种公告 （第 32 号）》( ...

人民财讯12月12日电，12月12日晚间，国家药监局官微发布中药保护品种公告(第32号)，根据《中药品 种保护条例》规定，国家药监局批准一品红（300723）生物医药有限公司的芩香清解口服液为首家中药 二级保护品种。保护期限自公告日起七年。一品红生物医药有限公司为一品红全资子公司。 ...

Group 1: Company Announcements - 蓝盾光电 announced the termination of the equity transfer agreement with Shanghai Xingsi Semiconductor, with no payment made for the equity transfer [1] - 兆新股份 plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, enhancing its capabilities in the renewable energy operation sector [2] - 南都电源 is in the process of planning a change in control and has suspended its stock trading, with the suspension expected to last no more than two trading days [3] - 万科A reported a guarantee balance of 84.476 billion yuan as of October 31, with no overdue guarantee matters [4] - 国晟科技's stock price has increased significantly, with a cumulative rise of 206.62%, indicating potential irrational speculation and risks of a rapid price drop [5] - 中威电子 announced a change in its actual controller to Fu Yingbo, with stock trading set to resume [6] Group 2: Mergers and Acquisitions - 新兴铸管's subsidiary plans to acquire 100% of China Resources Steel for 1.244 billion yuan [7] Group 3: Share Transfers and Investments - 太龙药业's shareholder plans to transfer 50.1 million shares to Jiangyao Holdings [8] - 医药 approvals include 常山药业 receiving a drug registration certificate for heparin sodium injection in Turkmenistan [9] - 真兰仪表's shareholder intends to increase holdings by 10 to 20 million yuan [9] - 海南瑞泽's vice president plans to reduce holdings by 231,000 shares [9] - 金陵体育's director has reduced holdings by 0.0276% [9] - 佰仁医疗's subsidiary has received approval for a collagen implant product [9]

Group 1 - Pro Pharmaceutical has obtained a food production license for bat moth mycelium powder, categorized as a health food [1] - Zhongqi Co., Ltd. has had its application for issuing convertible bonds accepted by the Shenzhen Stock Exchange [2] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind for facial dermal injections in China [3] Group 2 - Sinopharm Modern's subsidiary has received a drug registration certificate for Bumetanide injection, used for edema, hypertension, and preventing acute kidney failure [4] - Landun Optoelectronics has terminated the purchase of a stake in Star Si Semiconductor, with no payment made for the equity transfer [5] - Zhaoxin Co., Ltd. plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, positioning it as a controlling subsidiary [6] Group 3 - Chongqing Rural Commercial Bank has had the qualifications of three non-executive directors approved, effective immediately [7] - Changshan Pharmaceutical has received a drug registration certificate for Heparin Sodium injection in Turkmenistan, used for anticoagulation [8] - Changshan Pharmaceutical's vice president has resigned for personal reasons but will continue to hold other positions within the company [9] Group 4 - Shaanxi Construction has won five major projects with a total bid amount exceeding 3.912 billion yuan, covering various sectors [10][11] - Huazhong Co., Ltd. reported a 1.6% month-on-month increase in pig sales revenue for November, with a total of 34.4 million yuan [12] - Yipin Hong's subsidiary has received a drug registration certificate for Levofloxacin oral solution, effective for treating various bacterial infections [13] Group 5 - Yabo Co., Ltd.'s subsidiary has won projects totaling 7.2933 million yuan, representing 2.13% of the company's audited revenue for 2024 [14] - Sunshine Nuohe plans to invest 20 million yuan in Biling Bio, acquiring a 2.0435% stake in the company focused on nanomedicine [15] - Jinzhi Technology has won projects totaling 76.172 million yuan, accounting for 4.3% of the company's projected revenue for 2024 [16]

格隆汇12月11日丨一品红(300723.SZ)公布，全资子公司广州一品红制药有限公司于近日收到国家药品 监督管理局核准签发的关于左氧氟沙星口服溶液的《药品注册证书》，根据核准的说明书，左氧氟沙星 口服溶液适应症为：可用于治疗成年人（≥18岁）由金黄色葡萄球菌、铜绿假单胞菌、粘质沙雷氏菌、 大肠埃希菌、肺炎克雷伯杆菌、流感嗜血杆菌、肺炎链球菌等细菌的敏感菌株所引起的下列轻、中、重 度感染，包括：医院获得性肺炎、社区获得性肺炎、急性细菌性鼻窦炎、慢性支气管炎的急性细菌性发 作、复杂性皮肤及皮肤结构感染、非复杂性皮肤及皮肤软组织感染、慢性细菌性前列腺炎、复杂性尿路 感染、急性肾盂肾炎、非复杂性尿路感染、吸入性炭疽（暴露后）等适应症。左氧氟沙星是第三代喹诺 酮类药物，主要作用机制为抑制细菌DNA旋转酶的活性，阻碍细菌DNA的复制。它具有抗菌谱广、抗 菌作用强的特点。 责任编辑：安东 股票频道更多独家策划、专家专栏，免费查阅>> ...

Group 1 - The core point of the article is that Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Levofloxacin oral solution, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] - The drug has a wide range of indications and can be used to treat various bacterial infections [1] - The estimated sales scale of Levofloxacin in domestic urban and county-level public hospitals is approximately 401 million yuan in 2024 [1] Group 2 - The approval allows the company to have domestic sales qualifications, which will enrich its product pipeline and enhance its competitiveness in the anti-infection field [1] - There is a potential risk that sales after the drug's launch may not meet expectations [1]

人民财讯12月11日电，一品红（300723）12月11日公告，公司全资子公司广州一品红制药有限公司于近 日收到国家药品监督管理局核准签发的关于左氧氟沙星口服溶液的《药品注册证书》。左氧氟沙星口服 溶液可用于治疗成年人(≥18岁)由金黄色葡萄球菌、铜绿假单胞菌、粘质沙雷氏菌、大肠埃希菌、肺炎 克雷伯杆菌、流感嗜血杆菌、肺炎链球菌等细菌的敏感菌株所引起的下列轻、中、重度感染。 ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监 督管理局核准签发的关于左氧氟沙星口服溶液的《药品注册证书》。左氧氟沙星是第三代喹诺酮类药 物，主要作用机制为抑制细菌DNA旋转酶的活性，阻碍细菌DNA的复制。它具有抗菌谱广、抗菌作用 强的特点。 ...

智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于左氧氟沙星口服溶液的《药品注册证书》。左氧氟沙星是第三代喹诺酮类 药物，主要作用机制为抑制细菌DNA旋转酶的活性，阻碍细菌DNA的复制。它具有抗菌谱广、抗菌作 用强的特点。 ...

证券代码：300723 证券简称：一品红 公告编号：2025-084 一品红药业集团股份有限公司 关于全资子公司获得左氧氟沙星口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于左氧氟沙星口服 溶液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：左氧氟沙星口服溶液 英文名/拉丁名：Levofloxacin Oral Solution 主要成份：左氧氟沙星 剂 型：口服溶液剂 注册分类：化学药品 3 类 规 格：100ml:2.5g（按 C18H20FN3O4计） 药品注册标准编号：YBH30682025 药品有效期：12 个月 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上市许可持有人：广州一品红制药有限 ...